報價延遲最少15分鐘:2025/06/01 05:22 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.1817 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.27/--
|
|
企業價值
6.22M
|
| 資產負債 |
|
每股賬面淨值
0.02
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/01 05:22 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drugportfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301. |